Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), or connected persons, in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The filing reports an increase in the actual interests of specific PDMRs in American Depositary Shares (ADSs). These increases resulted from the re-investment of dividends paid on ADSs held in the vested portion of the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards. The transactions occurred at a price of $47.60 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share activity.
Important Facts for Investors
- Transaction Type: Increase in ADS holdings by PDMRs via dividend re-investment.
- Transaction Price: $47.60 per ADS.
- Specific Individuals: Mr. W C Louv (36.92 ADSs) and V A Whyte, Company Secretary.
- Plan Source: GSK 2009 Deferred Annual Bonus Plan Post-Tax awards.
- Reporting Date: April 20, 2015.